Skip to content

Jason P Rhodes, Director at Dyne Therapeutics, sold DYN on Aug 14, 2026

Data as of Oct 16

▼ SELL$8.1M322,465 shares at $25.00Jason P Rhodes DirectorDYN Dyne Therapeutics, Inc.
Watch DYN
Traded
Aug 14, 2026
Disclosed
Aug 17, 2026
Filed
3 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Jason P Rhodes, Director at Dyne Therapeutics, sold DYN on Aug 14, 2026TRADEDDISCLOSED
DYNSimilar stocks (XLV — its sector index fund), rebased to DYN's price on the disclosure day
DYN since disclosure
−45.5%
after the sale
Similar stocks (XLV) since disclosure
+5.8%
XLV — its sector index fund

Change in closing price from Aug 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$12Mdisclosed Aug 17 · filed 3 days after the trade
  2. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$34Mdisclosed Aug 17 · filed 3 days after the trade
  3. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$1.7Mdisclosed Aug 17 · filed 4 days after the trade
  4. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$7Mdisclosed Aug 17 · filed 4 days after the trade
  5. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$2.5Mdisclosed Aug 17 · filed 4 days after the trade

See every trade on DYN →